Stock Price, News, Quote and Profile of QUOIN PHARMACEUTICALS LT-ADR(NASDAQ:QNRX) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (4/24/2024, 7:25:09 PM)

Premarket: 0.7 +0.07 (+10.74%)

0.6321

-0.03 (-4.23%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap2.33M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Quoin Pharmaceuticals Ltd is a IL-based company operating in Biotechnology industry. Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Company Info

QUOIN PHARMACEUTICALS LT-ADR

23 Ha'Taas St.

Kfar Saba

P: 97299741444

CEO: Shai Yarkoni

Employees: 4

Website: https://quoinpharma.com/

QNRX News

a month ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive...

2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

2 months ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...